Liquid Biopsy Genetic Analysis Services Through Collaboration with RIKEN GENESIS
First written in FY2017-Q1. 6 of 10 entries say "Restated". Latest entry: FY2020-Q3.
0 other companies' latest entry also says "Restated".
- FY2020-Q3RestatedAnnual report
「We also worked to secure medical institutions to adopt our comprehensive cancer clinical sequencing service.」
Sales activities to secure medical institutions to adopt the clinical sequencing service for personalized medicine are continuing. - FY2020-Q2RestatedAnnual report
「We also worked to secure medical institutions to adopt our comprehensive cancer clinical sequencing service.」
Sales activities to secure medical institutions to adopt the clinical sequencing service for personalized medicine are continuing. - FY2019RestatedAnnual report
「We will promote business development by positioning companion diagnostic development support services and contracted clinical sequencing analysis services as growth drivers.」
The policy of making companion diagnostic development support and contracted clinical sequencing analysis growth drivers is being reaffirmed. - FY2019-Q3RestatedAnnual report
「We worked to expand services by leveraging our genetic analysis technology and extensive pathology diagnostic expertise, and sought to secure medical institutions to adopt our comprehensive cancer clinical sequencing service.」
Sales activities to secure medical institutions to adopt the clinical sequencing service for personalized medicine are continuing. - FY2018-Q3RestatedAnnual report
「The Advanced Healthcare Business launched contract cancer clinical sequencing analysis services using next-generation sequencers for lung, breast, ovarian, and colorectal cancers, malignant melanoma, and other conditions. It also entered into a sales agency agreement with 株式会社日立ハイテクノロジーズ in August of the previous year and worked to strengthen sales of contract cancer clinical sequencing analysis services using next-generation sequencers.」
The strengthening of sales through contracted cancer clinical sequencing analysis and distributor agreements is reiterated. - FY2018-Q1AdvancedAnnual report
「In addition, with respect to cancer clinical sequencing, we decided to participate in the Comprehensive Cancer Genetic Analysis: Precision Testing program, which will begin at Hokkaido Cancer Center in July this year.」
For personalized medicine analysis services, contracted cancer clinical sequencing analysis has begun, and participation in Hokkaido Cancer Center's Precision Testing program has also been decided. - FY2017RaisedAnnual report
「Going forward, the company will work to expand orders for analytical services that will make a significant contribution to companion diagnostic development using digital PCR, while also promoting its clinical sequencing business, which is expected to gain traction in the practice of personalized medicine, in an effort to restore performance.」
The scope of operations is expanding beyond liquid biopsy analysis using LBx® Probe to include digital PCR and clinical sequencing. - FY2017-Q3RestatedAnnual report
「In the advanced medical business, we entered into an agreement with ㈱理研ジェネシス on 26 April last year to collaborate on liquid biopsy genetic analysis and launched contracted genetic mutation analysis services for liquid biopsy samples using LBx® Probe, developed by that company.」
The contracted liquid biopsy genetic mutation analysis service using LBx® Probe, based on collaboration with ㈱理研ジェネシス, is reiterated. - FY2017-Q2AdvancedAnnual report
「In the advanced medical business, we entered into an agreement with ㈱理研ジェネシス on 26 April this year to collaborate on liquid biopsy genetic analysis and launched contracted genetic mutation analysis services for liquid biopsy samples using LBx® Probe, developed by that company.」
The service announced as a collaboration in the previous quarter is now described as having launched contracted liquid biopsy genetic mutation analysis services, clarifying that it has reached the service provision stage. - FY2017-Q1First statedAnnual report
「On 26 April this year, we entered into an agreement with ㈱理研ジェネシス to collaborate on liquid biopsy genetic analysis. We can now provide contracted genetic mutation analysis services using LBx® Probe, developed by that company, for liquid biopsy samples.」
Through collaboration with ㈱理研ジェネシス, the company became able to newly offer contracted liquid biopsy genetic mutation analysis services using LBx® Probe.